Open AccessMicrobiome, antibiotics and irritable bowel syndrome
Author(s) -
O. F. Ahmad,
Ayesha Akbar
Publication year - 2016
Publication title -
british medical bulletin
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.08
H-Index - 112
eISSN - 1471-8391
pISSN - 0007-1420
DOI - 10.1093/bmb/ldw038
Subject(s) - rifaximin , irritable bowel syndrome , medicine , microbiome , gut flora , antibiotics , functional gastrointestinal disorder , clinical trial , randomized controlled trial , bioinformatics , intensive care medicine , gastroenterology , immunology , biology , microbiology and biotechnology
Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal (GI) disorder. Increasing evidence implicates the GI microbiota in IBS pathogenesis and its modulation represents an emerging therapeutic strategy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom